Oral Carnitine in Heart Failure Patients
Recruiting now Early Phase 1 NCT07201714
Run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · for 18 and older · All sexes
What this study is about
Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.
Who can join (things the study team will check)
✅ You may be able to join if…
- Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome
- Stage 1, 2, 3a, 3b, or 4 chronic kidney disease
- Age ≥ 18 years
- Able to speak and read English
- Willing and able to provide consent
🚫 You may not be able to join if…
- Estimated GFR <15 mL/min/1.73m2 or Stage 5 chronic kidney disease
- Currently undergoing renal replacement therapy of any kind
- Pregnant, breastfeeding or intending pregnancy
- History of seizures of any type
- Known allergy to levocarnitine, magnesium stearate, microcrystalline cellulose or povidone
- Unable to provide consent
Where this trial is running
- London Health Sciences Centre, London, Ontario, Canada
Who to contact
Kathy Koyle · 519-685-8500 · kathleen.koyle@lhsc.on.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07201714.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.